Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pancreatic cancer

Clinical practice guidelines — what is the evidence?

In three practice guidelines from ASCO, experts provide evidence-based recommendations that address overarching clinical questions for the management of patients with pancreatic cancer. These guidelines offer improved strategies for interdisciplinary patient management and highlight the need for further research in several areas.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Khorana, A. A. et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2541–2556 (2016).

    Article  Google Scholar 

  2. 2

    Balaban, E. P. et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2654–2668 (2016).

    Article  Google Scholar 

  3. 3

    Sohal, D. P. et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. (2016).

  4. 4

    Bockhorn, M. et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155, 977–988 (2014).

    Article  Google Scholar 

  5. 5

    Chandrasegaram, M. D. et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br. J. Surg. 102, 1459–1472 (2015).

    CAS  Article  Google Scholar 

  6. 6

    Strobel, O. et al. Pancreatic cancer surgery: the new R-status counts. Ann. Surg. (2016).

  7. 7

    Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073–1081 (2010).

    CAS  Article  Google Scholar 

  8. 8

    Neoptolemos, J. P. et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J. Clin. Oncol. Abstr. 34, aLBA4006 (2016).

    Article  Google Scholar 

  9. 9

    Strobel, O. et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann. Surg. 261, 961–969 (2015).

    Article  Google Scholar 

  10. 10

    Allen, P. J. et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann. Surg. (2016).

  11. 11

    Suker, M. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 17, 801–810 (2016).

    CAS  Article  Google Scholar 

  12. 12

    Hackert, T. et al. Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients. Ann. Surg. (2016).

Download references

Author information



Corresponding author

Correspondence to Markus W. Büchler.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Strobel, O., Büchler, M. Clinical practice guidelines — what is the evidence?. Nat Rev Clin Oncol 13, 593–594 (2016).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing